{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:12:27Z","timestamp":1790838747716,"version":"4.1.0"},"reference-count":330,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Materials Today Bio"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.mtbio.2026.103569","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:13:18Z","timestamp":1786979598000},"page":"103569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["From neuroinflammation to immune reprogramming: Nanozyme-Integrated nanoplatforms for neuroimmune modulation in Parkinson's disease"],"prefix":"10.1016","volume":"40","author":[{"given":"Shu","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9820-2078","authenticated-orcid":false,"given":"Ghulam Md","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.mtbio.2026.103569_bib1","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afad186","article-title":"New horizons in Parkinson's disease in older populations","volume":"52","author":"Chhetri","year":"2023","journal-title":"Age Ageing"},{"issue":"10","key":"10.1016\/j.mtbio.2026.103569_bib2","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1097\/MS9.0000000000001142","article-title":"Parkinson's disease updates: addressing the pathophysiology, risk factors, genetics, diagnosis, along with the medical and surgical treatment","volume":"85","author":"Prajjwal","year":"2023","journal-title":"Ann. Med. Surg."},{"issue":"77","key":"10.1016\/j.mtbio.2026.103569_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.26416\/Psih.77.2.2024.9738","article-title":"Clinical features of psychiatric disorders in Parkinson's disease","volume":"2","author":"Stroe","year":"2024","journal-title":"Psihiatru. Ro"},{"key":"10.1016\/j.mtbio.2026.103569_bib4","first-page":"17","article-title":"Burden of non-motor symptoms of Parkinson's disease: cost-of-illness and quality-of-life estimates through a scoping review","author":"Meer","year":"2024","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"issue":"9","key":"10.1016\/j.mtbio.2026.103569_bib5","article-title":"Deep brain stimulation in the treatment of Parkinson's disease","volume":"14","author":"Shah","year":"2022","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.mtbio.2026.103569_bib6","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41582-024-01034-x","article-title":"Parkinson disease therapy: current strategies and future research priorities","volume":"20","author":"Stocchi","year":"2024","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/neup.12812","article-title":"Neuropathology of \u03b1-synuclein in Parkinson's disease","volume":"42","author":"Choong","year":"2022","journal-title":"Neuropathology"},{"key":"10.1016\/j.mtbio.2026.103569_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/1179069518761360","article-title":"The convergence of dopamine and \u03b1-Synuclein: implications for Parkinson's disease","volume":"12","author":"Mor","year":"2018","journal-title":"J. Exp. Neurosci."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41583-020-0263-9","article-title":"Immune cell regulation of glia during CNS injury and disease","volume":"21","author":"Greenhalgh","year":"2020","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.mtbio.2026.103569_bib10","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3389\/fncel.2018.00458","article-title":"The Interleukin-10 family of cytokines and their role in the CNS","volume":"12","author":"Burmeister","year":"2018","journal-title":"Front. Cell. Neurosci."},{"issue":"23","key":"10.1016\/j.mtbio.2026.103569_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242316766","article-title":"The role of immune dysfunction in Parkinson's disease development","volume":"24","author":"Cossu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.mtbio.2026.103569_bib12","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1093\/brain\/awae177","article-title":"The immune system in Parkinson's disease: what we know so far","volume":"147","author":"Roodveldt","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.mtbio.2026.103569_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2025.1575022","article-title":"Neuroimmune crosstalk in chronic neuroinflammation: microglial interactions and immune modulation","volume":"19","author":"M\u00fcller","year":"2025","journal-title":"Front. Cell. Neurosci."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib13","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/ejn.14290","article-title":"Immune system responses in Parkinson's disease: early and dynamic","volume":"49","author":"Tansey","year":"2018","journal-title":"Eur. J. Neurosci."},{"issue":"S1","key":"10.1016\/j.mtbio.2026.103569_bib15","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.2022.36.S1.R4474","article-title":"Aggregated alpha\u2010synuclein activates pro\u2010inflammatory NFKB signaling pathways through TLR\u2010Dependent and independent mechanisms in peripheral monocytic cells","volume":"36","author":"Bearoff","year":"2022","journal-title":"FASEB J."},{"key":"10.1016\/j.mtbio.2026.103569_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.parkreldis.2021.09.007","article-title":"Toll-like receptor 4 deficiency facilitates \u03b1-synuclein propagation and neurodegeneration in a mouse model of prodromal Parkinson's disease","volume":"91","author":"Venezia","year":"2021","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.mtbio.2026.103569_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1515052","article-title":"Editorial: glial crosstalk in neurological disorders","volume":"12","author":"Miyazaki","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"issue":"8","key":"10.1016\/j.mtbio.2026.103569_bib18","article-title":"An insight into the molecular mechanisms of neuroinflammation","volume":"38","author":"Mohammed","year":"2024","journal-title":"J. Biol. Regul. Homeost. Agents"},{"issue":"11","key":"10.1016\/j.mtbio.2026.103569_bib19","doi-asserted-by":"crossref","first-page":"9144","DOI":"10.3390\/ijms24119144","article-title":"Microglia and the blood-brain barrier: an external player in acute and chronic neuroinflammatory conditions","volume":"24","author":"Gullotta","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.mtbio.2026.103569_bib20","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000521710","article-title":"Interleukin-10 attenuates behavioral, immune and neurotrophin changes induced by chronic central administration of Interleukin-1\u03b2 in rats","volume":"29","author":"Zhang","year":"2022","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.mtbio.2026.103569_bib21","series-title":"Parkinson's Targeting: a Novel Drug Delivery Approach","author":"Ahirrao","year":"2024"},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1871527322666230330093829","article-title":"Blood-brain barrier and neurovascular unit dysfunction in pParkinson's disease: from clinical insights to pathogenic mechanisms and novel therapeutic approaches","volume":"23","author":"Khor","year":"2024","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"issue":"20","key":"10.1016\/j.mtbio.2026.103569_bib23","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1021\/acschemneuro.1c00118","article-title":"New blood-brain barrier models using primary Parkinson's disease rat brain endothelial cells and astrocytes for the development of central nervous system drug delivery systems","volume":"12","author":"Cai","year":"2021","journal-title":"ACS Chem. Neurosci."},{"issue":"9","key":"10.1016\/j.mtbio.2026.103569_bib24","article-title":"Parkinson's disease: current status, diagnosis, and treatment using nanomedicines","volume":"6","author":"Hasan","year":"2023","journal-title":"Adv. Therapeut."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib25","doi-asserted-by":"crossref","DOI":"10.47611\/jsrhs.v13i2.6775","article-title":"Nanotechnology for neurological disorders: application of nanotechnology in diagnosing and treating neurodegenerative diseases","volume":"13","author":"Haswani","year":"2024","journal-title":"J. Stud. Res."},{"key":"10.1016\/j.mtbio.2026.103569_bib26","series-title":"Neuropathology of Parkinson's Disease","first-page":"82","author":"El-Mansoury","year":"2023"},{"key":"10.1016\/j.mtbio.2026.103569_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.1036123","article-title":"Key brain cell interactions and contributions to the pathogenesis of Alzheimer's disease","volume":"10","author":"Saavedra","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.mtbio.2026.103569_bib32","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41577-025-01129-6","article-title":"Immune control of brain physiology","volume":"25","author":"Kovacs","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.mtbio.2026.103569_bib63","series-title":"Dopamine: Understanding its Synthesis, Receptors, and Influence on Neurological Functions","author":"Madhan","year":"2024"},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib64","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3390\/biomedicines13020492","article-title":"The role of dopamine in neurological, psychiatric, and metabolic disorders and cancer: a complex web of interactions","volume":"13","author":"Speranza","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.mtbio.2026.103569_bib65","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.3389\/fimmu.2018.02576","article-title":"Microglia: immune regulators of neurodevelopment","volume":"9","author":"Cowan","year":"2018","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.mtbio.2026.103569_bib66","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1254\/fpj.23005","article-title":"Microglia: a potential target for neurological disorder","volume":"158","author":"Parajuli","year":"2023","journal-title":"Folia Pharmacol. Jpn."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib45","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev-neuro-112723-035356","article-title":"Astrocytes as key regulators of neural signaling in health and disease","volume":"48","author":"Won","year":"2025","journal-title":"Annu. Rev. Neurosci."},{"issue":"12","key":"10.1016\/j.mtbio.2026.103569_bib67","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1007\/s11064-024-04241-6","article-title":"Progress of astrocyte-neuron crosstalk in central nervous system diseases","volume":"49","author":"Zhang","year":"2024","journal-title":"Neurochem. Res."},{"issue":"10","key":"10.1016\/j.mtbio.2026.103569_bib68","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041359","article-title":"Oligodendrocytes: myelination, plasticity, and axonal support","volume":"16","author":"Simons","year":"2024","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.mtbio.2026.103569_bib69","series-title":"Neuroglia: Function and Pathology","first-page":"295","article-title":"Chapter 5 - oligodendroglial physiology and function","author":"Verkhratsky","year":"2023"},{"issue":"12","key":"10.1016\/j.mtbio.2026.103569_bib70","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.3390\/ijms26125843","article-title":"Brain endothelial cells in blood-brain barrier regulation and neurological therapy","volume":"26","author":"Xiang","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib71","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/joim.13263","article-title":"Developmental regulation of barrier- and non-barrier blood vessels in the CNS","volume":"292","author":"Ben\u2010Zvi","year":"2021","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.mtbio.2026.103569_bib72","volume":"30","author":"Drozd","year":"2025"},{"issue":"4","key":"10.1016\/j.mtbio.2026.103569_bib73","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3390\/biom13040711","article-title":"A soluble platelet-derived growth factor Receptor-\u03b2 originates via Pre-mRNA splicing in the healthy brain and is upregulated during hypoxia and aging","volume":"13","author":"Payne","year":"2023","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib74","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/brain\/awad304","article-title":"Brain perivascular macrophages: current understanding and future prospects","volume":"147","author":"Wen","year":"2023","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib75","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/s41419-025-07592-2","article-title":"Perivascular macrophages in the central nervous system: insights into their roles in health and disease","volume":"16","author":"Zhan","year":"2025","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib76","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/cei\/uxac123","article-title":"Treg specialization and functions beyond immune suppression","volume":"211","author":"Astarita","year":"2022","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib77","doi-asserted-by":"crossref","first-page":"2","DOI":"10.65116\/vitascientia.V1I1.sc.1","article-title":"Strategic diplomats of immunity: rethinking tregs as rheostats of immune regulation","volume":"1","author":"Jain","year":"2025","journal-title":"Vita Scientia"},{"issue":"Suppl 5","key":"10.1016\/j.mtbio.2026.103569_bib78","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.3389\/fimmu.2019.01140","article-title":"The role of monocytes and macrophages in autoimmune diseases: a comprehensive review","volume":"10","author":"Ma","year":"2019","journal-title":"Front. Immunol."},{"issue":"6304","key":"10.1016\/j.mtbio.2026.103569_bib79","article-title":"Role of macrophages in neuroimmune regulation","volume":"16","author":"Xiao","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mtbio.2026.103569_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1213320","article-title":"Mast cell-mediated immune regulation in health and disease","volume":"10","author":"Dileepan","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.mtbio.2026.103569_bib81","article-title":"Role and mechanisms of mast cells in brain disorders","volume":"15","author":"Huang","year":"2024","journal-title":"Front. Immunol."},{"issue":"Pt 3","key":"10.1016\/j.mtbio.2026.103569_bib27","article-title":"The multiple faces of extracellular vesicles released by microglia: where are we 10 years after?","volume":"16","author":"Gabrielli","year":"2022","journal-title":"Front. Cell. Neurosci."},{"issue":"10","key":"10.1016\/j.mtbio.2026.103569_bib28","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3390\/biology10100948","article-title":"Neuron-derived extracellular vesicles modulate microglia activation and function","volume":"10","author":"Peng","year":"2021","journal-title":"Biology"},{"key":"10.1016\/j.mtbio.2026.103569_bib29","series-title":"Parkinson's Disease Involving Glial Cell Dysfunction","first-page":"164","author":"Oukhrib","year":"2023"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/jnc.14605","article-title":"Astrocyte support is important for the compensatory potential of the nigrostriatal system neurons during early neurodegeneration","volume":"148","author":"Kuter","year":"2018","journal-title":"J. Neurochem."},{"issue":"10","key":"10.1016\/j.mtbio.2026.103569_bib33","first-page":"3361","article-title":"Preface to the special issue \u201cneuroimmunology\u201d","volume":"168","author":"Godbout","year":"2024","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mtbio.2026.103569_bib34","series-title":"Cell Signaling","first-page":"126","article-title":"Immunological and neuron synapses","author":"Khalid","year":"2025"},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1759-1961.2010.00007.x","article-title":"Microglia as immune effectors of the central nervous system: expression of cytokines and chemokines","volume":"1","author":"Kim","year":"2010","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"10.1016\/j.mtbio.2026.103569_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.623771","article-title":"Glia-derived extracellular vesicles: role in central nervous system communication in health and disease","volume":"8","author":"Pistono","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib37","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nrn.2015.29","article-title":"Extracellular vesicles round off communication in the nervous system","volume":"17","author":"Budnik","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.mtbio.2026.103569_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1577809","article-title":"Microglial dynamics and emerging therapeutic strategies in CNS homeostasis and pathology","volume":"16","author":"Cao","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.mtbio.2026.103569_bib39","series-title":"Functional Roles in Health and Disease","first-page":"3","article-title":"An introduction to CNS-resident microglia: definitions, assays","author":"Davis","year":"2012"},{"key":"10.1016\/j.mtbio.2026.103569_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1188672","article-title":"Brain-derived neurotrophic factor (BDNF) has direct anti-inflammatory effects on microglia","volume":"17","author":"Charlton","year":"2023","journal-title":"Front. Cell. Neurosci."},{"issue":"19","key":"10.1016\/j.mtbio.2026.103569_bib41","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1523\/JNEUROSCI.2539-20.2021","article-title":"Selective ablation of BDNF from microglia reveals novel roles in self-renewal and hippocampal neurogenesis","volume":"41","author":"Harley","year":"2021","journal-title":"J. Neurosci."},{"issue":"12","key":"10.1016\/j.mtbio.2026.103569_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2023.100678","article-title":"Identification of state-specific proteomic and transcriptomic signatures of microglia-derived extracellular vesicles","volume":"22","author":"Santiago","year":"2023","journal-title":"Mol. Cell. Proteomics : MCP"},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib43","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/biom16020224","article-title":"Activated microglia-derived extracellular vesicles elicit a pro-inflammatory astrocytic response via cargo-dependent mechanisms","volume":"16","author":"Scheld","year":"2026","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib44","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/brainsci10030168","article-title":"No longer underappreciated: the emerging concept of astrocyte heterogeneity in neuroscience","volume":"10","author":"Pestana","year":"2020","journal-title":"Brain Sci."},{"issue":"4","key":"10.1016\/j.mtbio.2026.103569_bib46","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/14728222.2021.1915993","article-title":"Targeting neuroprotective functions of astrocytes in neuroimmune diseases","volume":"25","author":"Klegeris","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib47","doi-asserted-by":"crossref","first-page":"46","DOI":"10.18821\/1560-9561-2018-21-1-46-53","article-title":"Astrocytes and their role in the pathology of the central nervous system","volume":"21","author":"Gorbacheva","year":"2019","journal-title":"Russ. Pediatr. J."},{"key":"10.1016\/j.mtbio.2026.103569_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2023.1305949","article-title":"Blocking of microglia-astrocyte proinflammatory signaling is beneficial following stroke","volume":"16","author":"Prescott","year":"2024","journal-title":"Front. Mol. Neurosci."},{"issue":"4","key":"10.1016\/j.mtbio.2026.103569_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202350482","article-title":"Regulation of autoimmune-mediated neuroinflammation by endothelial cells","volume":"54","author":"Kallal","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.mtbio.2026.103569_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1233908","article-title":"Immune cells as messengers from the CNS to the periphery: the role of the meningeal lymphatic system in immune cell migration from the CNS","volume":"14","author":"Laaker","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib51","doi-asserted-by":"crossref","DOI":"10.1117\/1.NPh.9.3.031914","article-title":"Immune-vascular mural cell interactions: consequences for immune cell trafficking, cerebral blood flow, and the blood-brain barrier","volume":"9","author":"Barkaway","year":"2022","journal-title":"Neurophotonics"},{"key":"10.1016\/j.mtbio.2026.103569_bib52","series-title":"Alterations in Blood\u2012Brain Barrier (BBB) Integrity Related to Proinflammatory Cytokines","author":"Gryka-Marton","year":"2024"},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevImmunol.2022045080","article-title":"Regulatory T cell therapeutics for neuroinflammatory disorders","volume":"42","author":"Harkins","year":"2022","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.mtbio.2026.103569_bib54","series-title":"The Roles of Regulatory T Cells in Central Nervous System Autoimmunity","author":"Keating","year":"2019"},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib55","doi-asserted-by":"crossref","DOI":"10.37819\/hb.2.2017","article-title":"The potential role of intestinal macrophages in the gut-brain axis","volume":"3","author":"Jiang","year":"2024","journal-title":"Human Brain"},{"issue":"11","key":"10.1016\/j.mtbio.2026.103569_bib56","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/s41423-025-01333-3","article-title":"Beyond the gut: decoding the gut\u2013immune\u2013brain axis in health and disease","volume":"22","author":"Park","year":"2025","journal-title":"Cell. Mol. Immunol."},{"issue":"13","key":"10.1016\/j.mtbio.2026.103569_bib57","doi-asserted-by":"crossref","first-page":"7041","DOI":"10.3390\/ijms25137041","article-title":"Extracellular vesicles as mediators of neuroinflammation in intercellular and inter-organ crosstalk","volume":"25","author":"Cabrera-Pastor","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib58","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s41232-024-00352-3","article-title":"Peripheral and central regulation of neuro\u2013immune crosstalk","volume":"44","author":"Izumi","year":"2024","journal-title":"Inflamm. Regen."},{"key":"10.1016\/j.mtbio.2026.103569_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fragi.2025.1549848","article-title":"CX3CR1 upregulation modulates microglial activation and preserves synapses in the hippocampus and frontal cortex of middle-aged mice","volume":"6","author":"Liu","year":"2025","journal-title":"Front. Aging"},{"issue":"11","key":"10.1016\/j.mtbio.2026.103569_bib60","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.3390\/biomedicines12112468","article-title":"TGF-\u03b2 signaling in microglia: a key regulator of development, homeostasis and reactivity","volume":"12","author":"Li","year":"2024","journal-title":"Biomedicines"},{"issue":"21","key":"10.1016\/j.mtbio.2026.103569_bib61","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1113\/jphysiol.2010.199489","article-title":"What are chemokine signalling systems doing in the brain?","volume":"588","author":"Miles","year":"2010","journal-title":"J. Physiol."},{"key":"10.1016\/j.mtbio.2026.103569_bib62","series-title":"Modulation of Neuronal Cell Cycle Proteins by Chemokine Receptors and its Role in the Survival of Postmitotic Neurons","author":"Khan","year":"2009"},{"issue":"9","key":"10.1016\/j.mtbio.2026.103569_bib82","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1007\/s00204-025-04088-y","article-title":"An update on the involvement of inflammatory mediators in Parkinson's disease pathogenesis","volume":"99","author":"Verma","year":"2025","journal-title":"Arch. Toxicol."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib83","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.3390\/ijms25031641","article-title":"What can inflammation tell us about therapeutic strategies for Parkinson's disease?","volume":"25","author":"Xue","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mtbio.2026.103569_bib84","article-title":"Sequential extraction of soluble and insoluble alpha-synuclein from parkinsonian brains","volume":"107","author":"Bandopadhyay","year":"2016","journal-title":"J. Vis. Exp."},{"issue":"107","key":"10.1016\/j.mtbio.2026.103569_bib85","doi-asserted-by":"crossref","DOI":"10.3791\/53415","article-title":"Sequential extraction of soluble and insoluble alpha-synuclein from parkinsonian brains","volume":"10","author":"Bandopadhyay","year":"2016","journal-title":"J. Vis. Exp."},{"issue":"5","key":"10.1016\/j.mtbio.2026.103569_bib86","doi-asserted-by":"crossref","first-page":"547","DOI":"10.5607\/en.2019.28.5.547","article-title":"Targeting microglial and neuronal toll-like receptor 2 in synucleinopathies","volume":"28","author":"Kwon","year":"2019","journal-title":"Exp. Neurobiol."},{"issue":"12","key":"10.1016\/j.mtbio.2026.103569_bib87","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13522","article-title":"\u03b1-synuclein suppresses microglial autophagy and promotes neurodegeneration in a mouse model of Parkinson's disease","volume":"20","author":"Tu","year":"2021","journal-title":"Aging Cell"},{"issue":"20","key":"10.1016\/j.mtbio.2026.103569_bib88","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1093\/hmg\/ddl242","article-title":"\u03b2-synuclein modulates \u03b1-synuclein neurotoxicity by reducing \u03b1-synuclein protein expression","volume":"15","author":"Fan","year":"2006","journal-title":"Hum. Mol. Genet."},{"issue":"2\u20133","key":"10.1016\/j.mtbio.2026.103569_bib89","first-page":"55","article-title":"Alpha-synuclein: the interplay of pathology, neuroinflammation, and environmental factors in Parkinson's disease","volume":"20","author":"He","year":"2021","journal-title":"Neurodegener. Dis."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib90","doi-asserted-by":"crossref","first-page":"11","DOI":"10.52600\/2965-0968.bjcmr.2025.3.1.bjcmr11","article-title":"The role of microglia in Parkinson's disease and possible therapeutic targets","volume":"3","author":"Gomes","year":"2025","journal-title":"Brazil. J. Clin. Med. Rev."},{"issue":"Suppl 1","key":"10.1016\/j.mtbio.2026.103569_bib91","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3233\/JPD-223237","article-title":"Microglia in Parkinson's disease","volume":"12","author":"Stefanova","year":"2022","journal-title":"J. Parkinsons Dis."},{"issue":"6","key":"10.1016\/j.mtbio.2026.103569_bib92","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/glia.23970","article-title":"\u03b1\u2010Synuclein evokes NLRP3 inflammasome\u2010mediated IL\u20101\u03b2 secretion from primary human microglia","volume":"69","author":"Pike","year":"2021","journal-title":"Glia"},{"issue":"6","key":"10.1016\/j.mtbio.2026.103569_bib93","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1007\/s11064-011-0439-9","article-title":"Lack of alpha-synuclein modulates microglial phenotype in vitro","volume":"36","author":"Austin","year":"2011","journal-title":"Neurochem. Res."},{"issue":"9","key":"10.1016\/j.mtbio.2026.103569_bib94","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.3390\/ijms22094676","article-title":"The contribution of microglia to neuroinflammation in Parkinson's disease","volume":"22","author":"Badanjak","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib95","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41531-024-00640-2","article-title":"Microglial inhibition alleviates alpha-synuclein propagation and neurodegeneration in Parkinson's disease mouse model","volume":"10","author":"Thi Lai","year":"2024","journal-title":"npj Parkinson's Dis."},{"key":"10.1016\/j.mtbio.2026.103569_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1506358","article-title":"Microglia: roles and genetic risk in Parkinson's disease","volume":"18","author":"Trainor","year":"2024","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.mtbio.2026.103569_bib97","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/978-3-031-64839-7_13","article-title":"The role of astrocytes in Parkinson's disease : astrocytes in Parkinson's disease","volume":"39","author":"Garcia","year":"2024","journal-title":"Adv. Neurobiol."},{"issue":"8","key":"10.1016\/j.mtbio.2026.103569_bib98","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70299","article-title":"Astrocyte in neurological disease: pathogenesis and therapy","volume":"6","author":"Huang","year":"2025","journal-title":"MedComm"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib99","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40478-023-01526-9","article-title":"Roles of neuropathology-associated reactive astrocytes: a systematic review","volume":"11","author":"Lawrence","year":"2023","journal-title":"Acta Neuropathol. Commun."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib100","doi-asserted-by":"crossref","first-page":"7047","DOI":"10.1038\/s41598-020-63766-2","article-title":"Innate immune functions of astrocytes are dependent upon tumor necrosis factor-alpha","volume":"10","author":"Rodgers","year":"2020","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib101","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/biology12020155","article-title":"The synucleins and the astrocyte","volume":"12","author":"Myers","year":"2023","journal-title":"Biology"},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib102","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/jnr.24994","article-title":"Impact of monomeric and aggregated wild\u2010type and A30P\/A53T double\u2010mutant \u03b1\u2010synuclein on antioxidant mechanism and glutamate metabolic profile of cultured astrocytes","volume":"100","author":"Raj","year":"2021","journal-title":"J. Neurosci. Res."},{"issue":"23","key":"10.1016\/j.mtbio.2026.103569_bib104","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314753","article-title":"Pathogenesis of \u03b1-Synuclein in Parkinson's disease: from a neuron-glia crosstalk perspective","volume":"23","author":"Yi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mtbio.2026.103569_bib158","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40035-024-00430-z","article-title":"Blood\u2013brain barrier alterations and their impact on Parkinson's disease pathogenesis and therapy","volume":"13","author":"Lau","year":"2024","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.mtbio.2026.103569_bib103","series-title":"Neuroinflammation and Oxidative Stress in Models of Parkinson's Disease and Protein-Misfolding Disorders","author":"Tjalkens","year":"2017"},{"key":"10.1016\/j.mtbio.2026.103569_bib105","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41531-025-01148-z","article-title":"Peripheral immune cell-specific genes in Parkinson's disease uncovered by multi-omics with therapeutic implications","volume":"11","author":"Hong","year":"2025","journal-title":"npj Parkinsons Dis"},{"key":"10.1016\/j.mtbio.2026.103569_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2025.1682006","article-title":"Peripheral\u2013central immune interactions in Parkinson's disease: insights into innate and adaptive immunity","volume":"18","author":"Tumpa","year":"2025","journal-title":"Front. Mol. Neurosci."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib107","article-title":"T-cell based immunotherapies for Parkinson's disease","volume":"1","author":"Pacheco","year":"2021","journal-title":"Explor. Neuroprot. Therap."},{"key":"10.1016\/j.mtbio.2026.103569_bib108","first-page":"670","volume":"52","author":"Sun","year":"2019"},{"key":"10.1016\/j.mtbio.2026.103569_bib109","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3389\/fimmu.2020.00947","article-title":"Interleukin-17 in chronic inflammatory neurological diseases","volume":"11","author":"Milovanovic","year":"2020","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib110","first-page":"223","article-title":"Effect of interaction between microglia and T cell on brain damage after ischemic stroke","volume":"27","author":"Liu","year":"2019","journal-title":"Int J Cerebrovasc Dis"},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib111","doi-asserted-by":"crossref","DOI":"10.4172\/2161-0460.1000148","article-title":"The inflammatory cytokines in the pathogenesis of Parkinson's disease","volume":"4","author":"Sadek","year":"2014","journal-title":"J. Alzheimers Dis. Parkinsonism"},{"issue":"6","key":"10.1016\/j.mtbio.2026.103569_bib112","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s12975-017-0545-3","article-title":"CCL11 (Eotaxin-1) levels predict long-term functional outcomes in patients following ischemic stroke","volume":"8","author":"Roy-O'Reilly","year":"2017","journal-title":"Trans. Stroke Res."},{"key":"10.1016\/j.mtbio.2026.103569_bib113","series-title":"Neuroprotective Actions of the Chemokine CXCL12","author":"Nicolai","year":"2010"},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib116","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s12640-021-00345-x","article-title":"Interferon-\u03b3 involvement in the neuroinflammation associated with Parkinson's disease and L-DOPA-Induced dyskinesia","volume":"39","author":"Ferrari","year":"2021","journal-title":"Neurotox. Res."},{"issue":"6","key":"10.1016\/j.mtbio.2026.103569_bib117","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1080\/01616412.2021.2024726","article-title":"Dopaminergic neuronal death in the substantia nigra associates with change in serum levels of TNF-\u03b1 and IL-1\u03b2; evidence from early experimental model of Parkinson's disease","volume":"44","author":"Piri","year":"2022","journal-title":"Neurol. Res."},{"issue":"7","key":"10.1016\/j.mtbio.2026.103569_bib118","article-title":"Targeting microglial \u03b1-Synuclein\/TLRs\/NF-kappaB\/NLRP3 inflammasome axis in Parkinson's disease","volume":"12","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.mtbio.2026.103569_bib119","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.3233\/JPD-223290","article-title":"Role of NLRP3 inflammasome in Parkinson's disease and therapeutic considerations","volume":"12","author":"Nguyen","year":"2022","journal-title":"J. Parkinsons Dis."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib120","doi-asserted-by":"crossref","first-page":"28","DOI":"10.59298\/INOSRAS\/2025\/13.1.2834000","article-title":"The dual role of cytokines in immunity: balancing pro-inflammatory and anti-inflammatory responses","volume":"13","author":"Geoffrey","year":"2025","journal-title":"INOSR Appl. Sci."},{"key":"10.1016\/j.mtbio.2026.103569_bib121","series-title":"Chemokine Receptors in Neuroinflammation","first-page":"351","author":"Cardona","year":"2007"},{"key":"10.1016\/j.mtbio.2026.103569_bib122","series-title":"CCL2 and Neuronal Inflammation: Implications for Neurodegenerative Diseases","author":"Zeng","year":"2023"},{"issue":"S1","key":"10.1016\/j.mtbio.2026.103569_bib123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fasebj.2020.34.s1.05585","article-title":"Peripheral inflammation drives TLR2 and IL\u20101R1 mediated neurodegeneration in Parkinson's disease","volume":"34","author":"Bearoff","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.mtbio.2026.103569_bib124","series-title":"Sustained Proinflammatory Signaling Contributes to Neurodegeneration in Parkinson's Disease","author":"Johnson","year":"2018"},{"key":"10.1016\/j.mtbio.2026.103569_bib125","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.3389\/fimmu.2019.01592","article-title":"Regulatory mechanisms of the NLRP3 inflammasome, a novel immune-inflammatory marker in cardiovascular diseases","volume":"10","author":"An","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08916934.2021.1995860","article-title":"The role of NLRP3 inflammasome in the pathogenesis of rheumatic disease","volume":"55","author":"Kong","year":"2021","journal-title":"Autoimmunity"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib127","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1111\/ejn.15242","article-title":"Nuclear factor-kappa B (NF-\u03baB) in pathophysiology of Parkinson disease: diverse patterns and mechanisms contributing to neurodegeneration","volume":"54","author":"Dolatshahi","year":"2021","journal-title":"Eur. J. Neurosci."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib128","first-page":"1","article-title":"Transcriptional factor NF-\u03baB as a target for therapy in Parkinson's disease","volume":"2011","author":"Flood","year":"2011","journal-title":"Parkinsons Dis."},{"issue":"4","key":"10.1016\/j.mtbio.2026.103569_bib129","first-page":"295","article-title":"Activation mechanism and physiological roles of stress-activated protein kinase\/c-Jun NH2-terminal kinase in mammalian cells","volume":"17","author":"Nishina","year":"2003","journal-title":"J. Biol. Regul. Homeost. Agents"},{"issue":"11","key":"10.1016\/j.mtbio.2026.103569_bib130","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1046\/j.1365-2443.2002.00591.x","article-title":"Neuronal p38 MAPK signalling: an emerging regulator of cell fate and function in the nervous system","volume":"7","author":"Takeda","year":"2002","journal-title":"Genes Cells"},{"issue":"7\u20139","key":"10.1016\/j.mtbio.2026.103569_bib131","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1089\/ars.2023.0002","article-title":"NADPH oxidases in neurodegenerative disorders: mechanisms and therapeutic opportunities","volume":"41","author":"Fiadeiro","year":"2024","journal-title":"Antioxid. Redox Signaling"},{"issue":"4","key":"10.1016\/j.mtbio.2026.103569_bib132","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/jpp\/rgab064","article-title":"Pharmacological intervention in oxidative stress as a therapeutic target in neurological disorders","volume":"74","author":"Sharma","year":"2022","journal-title":"J. Pharm. Pharmacol."},{"issue":"4","key":"10.1016\/j.mtbio.2026.103569_bib133","first-page":"628","article-title":"Research progress of CD4+T cells-mediated regulation of neuroinflammation involved in neurodegenerative diseases","volume":"43","author":"Chen","year":"2021","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Acad. Med. Sin."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib134","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12974-022-02605-9","article-title":"The role of the adaptive immune system and T cell dysfunction in neurodegenerative diseases","volume":"19","author":"Demaio","year":"2022","journal-title":"J. Neuroinflammation"},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib135","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1042\/BST20201092","article-title":"Leucine-rich repeat kinase 2-related functions in GLIA: an update of the last years","volume":"49","author":"Filippini","year":"2021","journal-title":"Biochem. Soc. Trans."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib136","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41531-025-01185-8","article-title":"Interferon gamma stimulates coordinated changes in LRRK2, GCase, and cathepsin activities in idiopathic and genetic Parkinson's disease monocytes","volume":"11","author":"Hughes","year":"2025","journal-title":"npj Parkinson's Dis."},{"key":"10.1016\/j.mtbio.2026.103569_bib137","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.conb.2021.09.005","article-title":"PTEN-induced kinase 1 (PINK1) and Parkin: unlocking a mitochondrial quality control pathway linked to Parkinson's disease","volume":"72","author":"Agarwal","year":"2021","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.mtbio.2026.103569_bib138","article-title":"Martinez, A., Sanchez-Martinez, A., Pickering, J.T. et al. Mitochondrial CISD1\/Cisd accumulation blocks mitophagy and genetic or pharmacological inhibition rescues neurodegenerative phenotypes in Pink1\/parkin models. Mol Neurodegeneration 19, 12 (2024)","author":"Martinez","year":"2023","journal-title":"Res. Square"},{"key":"10.1016\/j.mtbio.2026.103569_bib114","series-title":"Neuroinflammation During Parkinson's Disease: Key Cells and Molecules Involved in it","author":"Sinha","year":"2016"},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/952375","article-title":"Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease","volume":"2013","author":"More","year":"2013","journal-title":"Mediat. Inflamm."},{"issue":"6","key":"10.1016\/j.mtbio.2026.103569_bib139","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/ca.23083","article-title":"Blood brain barrier: a review of its anatomy and physiology in health and disease","volume":"31","author":"Sharif","year":"2018","journal-title":"Clin. Anat."},{"key":"10.1016\/j.mtbio.2026.103569_bib140","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/164_2023_689","article-title":"Blood-brain barrier (BBB)-crossing strategies for improved treatment of CNS disorders","volume":"284","author":"Zhang","year":"2023","journal-title":"Handb. Exp. Pharmacol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib141","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40035-024-00430-z","article-title":"Blood\u2013brain barrier alterations and their impact on Parkinson's disease pathogenesis and therapy","volume":"13","author":"Lau","year":"2024","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.mtbio.2026.103569_bib142","series-title":"Vascular Inflammation is a Risk Factor Associated with Brain Atrophy and Disease Severity in Parkinson's Disease: a case-control Study","author":"Yu","year":"2019"},{"issue":"24","key":"10.1016\/j.mtbio.2026.103569_bib143","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252413614","article-title":"Revolutionizing neuroimmunology: unraveling immune dynamics and therapeutic innovations in CNS disorders","volume":"25","author":"Toader","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.mtbio.2026.103569_bib144","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1007\/s11064-023-03904-0","article-title":"Mitochondrial dysfunction and Parkinson's disease: pathogenesis and therapeutic strategies","volume":"48","author":"Moradi Vastegani","year":"2023","journal-title":"Neurochem. Res."},{"issue":"s1","key":"10.1016\/j.mtbio.2026.103569_bib145","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1471-4159.2009.05897.x","article-title":"Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival","volume":"109","author":"Niizuma","year":"2009","journal-title":"J. Neurochem."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib146","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1080\/00207454.2016.1178261","article-title":"Antioxidant modulation in restoring mitochondrial function in neurodegeneration","volume":"127","author":"Pahrudin Arrozi","year":"2016","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.mtbio.2026.103569_bib147","series-title":"Priming is Dispensable for NLRP3 Inflammasome Activation in Human Monocytes","author":"Gritsenko","year":"2020"},{"issue":"6","key":"10.1016\/j.mtbio.2026.103569_bib148","article-title":"Hematopoietic cell Kinase (HCK) is essential for NLRP3 inflammasome activation and lipopolysaccharide-induced inflammatory response in vivo","volume":"11","author":"Kong","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.mtbio.2026.103569_bib149","series-title":"At the Intersection Between Mitochondrial Dysfunction and Lysosomal Autophagy: Role of PD-Related Neurotoxins and Gene Products","author":"Asiago","year":"2017"},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib150","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1021\/acschemneuro.8b00373","article-title":"Gene dysfunction mediates immune response to dopaminergic degeneration in Parkinson's disease","volume":"10","author":"Jiao","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.mtbio.2026.103569_bib151","series-title":"LRRK2 G2019S Variant is Associated with Transcriptional Changes in Parkinson's Disease Human Myeloid Cells Under Proinflammatory Environment","author":"Navarro","year":"2024"},{"issue":"9","key":"10.1016\/j.mtbio.2026.103569_bib152","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.2174\/1570159X16666180222165418","article-title":"The role of LRRK2 in neurodegeneration of parkinson disease","volume":"16","author":"Rui","year":"2018","journal-title":"Curr. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib153","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3233\/JPD-160989","article-title":"PINK1, parkin, and mitochondrial quality control: what can we learn about Parkinson's disease pathobiology?","volume":"7","author":"Truban","year":"2016","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.mtbio.2026.103569_bib154","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ceb.2017.03.013","article-title":"PINK1 and Parkin: emerging themes in mitochondrial homeostasis","volume":"45","author":"McWilliams","year":"2017","journal-title":"Curr. Opin. Cell Biol."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.47936\/encephalitis.2023.00031","article-title":"Peripheral blood inflammatory cytokines in prodromal and overt \u03b1-synucleinopathies: a review of current evidence","volume":"3","author":"Jun","year":"2023","journal-title":"Encephalitis"},{"issue":"8","key":"10.1016\/j.mtbio.2026.103569_bib156","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00702-010-0431-6","article-title":"Future directions for immune modulation in neurodegenerative disorders: focus on Parkinson's disease","volume":"117","author":"Maguire-Zeiss","year":"2010","journal-title":"J. Neural Transm."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib157","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/neuroglia6020017","article-title":"Central and peripheral immunity responses in Parkinson's disease: an overview and update","volume":"6","author":"Ebrahim","year":"2025","journal-title":"Neuroglia"},{"issue":"10","key":"10.1016\/j.mtbio.2026.103569_bib159","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1002\/cti2.1469","article-title":"Dopaminergic regulation of inflammation and immunity in Parkinson's disease: friend or foe?","volume":"12","author":"Furgiuele","year":"2023","journal-title":"Clin. Transl. Immunol."},{"issue":"22","key":"10.1016\/j.mtbio.2026.103569_bib160","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.3390\/ijms21228421","article-title":"Neurodegeneration and Inflammation-An interesting interplay in Parkinson's disease","volume":"21","author":"Marogianni","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mtbio.2026.103569_bib163","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13287-023-03280-0","article-title":"Pathological mechanisms of neuroimmune response and multitarget disease-modifying therapies of mesenchymal stem cells in Parkinson's disease","volume":"14","author":"Zhuo","year":"2023","journal-title":"Stem Cell Res. Ther."},{"issue":"6","key":"10.1016\/j.mtbio.2026.103569_bib161","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1039\/D1MD00036E","article-title":"Small molecule therapeutics for neuroinflammation-mediated neurodegenerative disorders","volume":"12","author":"Miller","year":"2021","journal-title":"RSC Med. Chem."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib162","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2478\/amma-2025-0018","article-title":"The impact of pharmacological agents on neuroinflammation in neurodegenerative diseases","volume":"71","author":"Sharma","year":"2025","journal-title":"Acta Marisiensis - Seria Medica"},{"issue":"5","key":"10.1016\/j.mtbio.2026.103569_bib164","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/1859431","article-title":"Role of astrocytic dysfunction in the pathogenesis of Parkinson's disease animal models from a molecular signaling perspective","volume":"2020","author":"Udovin","year":"2020","journal-title":"Neural Plast."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib165","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4103\/1673-5374.265541","article-title":"Genetic targeting of astrocytes to combat neurodegenerative disease","volume":"15","author":"Kirschen","year":"2019","journal-title":"Neural Regen. Res."},{"issue":"9","key":"10.1016\/j.mtbio.2026.103569_bib166","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.4103\/1673-5374.306064","article-title":"Astrocytes: a double-edged sword in neurodegenerative diseases","volume":"16","author":"Yan","year":"2021","journal-title":"Neural Regen. Res."},{"issue":"4","key":"10.1016\/j.mtbio.2026.103569_bib167","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/1073858421991066","article-title":"Neuroinflammation in Parkinson's disease: triggers, mechanisms, and immunotherapies","volume":"28","author":"Wang","year":"2021","journal-title":"Neuroscientist"},{"key":"10.1016\/j.mtbio.2026.103569_bib168","series-title":"TNF-Mediated Neuroinflammation is Linked to Neuronal Necroptosis in Alzheimer's Disease Hippocampus","author":"Jayaraman","year":"2021"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib169","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s40478-021-01264-w","article-title":"TNF-mediated neuroinflammation is linked to neuronal necroptosis in Alzheimer's disease hippocampus","volume":"9","author":"Jayaraman","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.mtbio.2026.103569_bib182","first-page":"1","article-title":"Regulatory mechanisms and therapeutic potential of natural microglia inhibitors in Parkinson's disease","author":"Jin","year":"2025","journal-title":"J. Asian Nat. Prod. Res."},{"issue":"4","key":"10.1016\/j.mtbio.2026.103569_bib183","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/glia.24664","article-title":"Microglial depletion, a new tool in neuroinflammatory disorders: comparison of pharmacological inhibitors oftheCSF-1R","volume":"73","author":"Guenoun","year":"2024","journal-title":"Glia"},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib184","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2025.5489","article-title":"NLRP3 inflammasome in health and disease (review","volume":"55","author":"Wang","year":"2025","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.mtbio.2026.103569_bib185","series-title":"Targeting Cytokine-Mediated Inflammation in Brain Disorders: Developing New Treatment Strategies","author":"Mallick","year":"2024"},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib186","article-title":"Novel therapeutic targets in neuroinflammation and neuropathic pain","volume":"1","author":"Ramesh","year":"2014","journal-title":"Inflamm. Cell Signal."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib187","article-title":"Targeting the pathogenesis and boosting the therapeutic efficacy of Parkinson's disease by advanced nanoparticles","volume":"2","author":"Liu","year":"2023","journal-title":"MedComm \u2013 Biomater. Appl."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib188","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2174\/1871527321666220310122415","article-title":"The immune system as a therapeutic target for old and new drugs in Parkinson's disease","volume":"22","author":"Comi","year":"2023","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"issue":"5","key":"10.1016\/j.mtbio.2026.103569_bib189","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s13311-022-01288-7","article-title":"Alpha-synuclein immunization strategies for synucleinopathies in clinical studies: a biological perspective","volume":"19","author":"Knecht","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.mtbio.2026.103569_bib190","series-title":"Ameliorating Mitochondrial Dysfunction for the Therapy of Parkinson's Disease","author":"Zheng","year":"2024"},{"issue":"11","key":"10.1016\/j.mtbio.2026.103569_bib191","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.3390\/pharmaceutics13111779","article-title":"Blood-brain barrier dysfunction in CNS disorders and putative therapeutic targets: an overview","volume":"13","author":"Archie","year":"2021","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.mtbio.2026.103569_bib192","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40263-026-01275-y","article-title":"Pathological protein targets in Parkinson's disease: progress towards the development of disease-modifying therapies","volume":"40","author":"Dzamko","year":"2026","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.mtbio.2026.103569_bib193","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/13543784.2020.1771693","article-title":"Immunization therapies for Parkinson's disease: state of the art and considerations for future clinical trials","volume":"29","author":"Antonini","year":"2020","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib178","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00415-024-12770-x","article-title":"An update on immune-based alpha-synuclein trials in Parkinson's disease","volume":"272","author":"Alfaidi","year":"2024","journal-title":"J. Neurol."},{"issue":"11","key":"10.1016\/j.mtbio.2026.103569_bib170","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/14728222.2024.2433130","article-title":"Chemokine signaling in tumors: potential role of CXC chemokines and their receptors as glioblastoma therapeutic targets","volume":"28","author":"Corsaro","year":"2024","journal-title":"Expert Opin. Ther. Targets"},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib171","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1254\/fpj.25005","article-title":"Involvement of chemokines and these receptors in glioblastoma. Nihon Yakurigaku Zasshi","volume":"160","author":"Hara","year":"2025","journal-title":"Folia Pharmacol. Jpn."},{"issue":"Suppl 1","key":"10.1016\/j.mtbio.2026.103569_bib172","article-title":"Blood-brain barrier-crossing IL-4 for treatment of neuroinflammatory disease 4663","volume":"214","author":"Kane Berg","year":"2025","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib173","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1515\/nipt-2025-0008","article-title":"Adaptive immunity in the pathogenesis and treatments of Parkinson's disease","volume":"4","author":"Du","year":"2025","journal-title":"Neuroimmune Pharmacol. Therapeut."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib174","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/cei\/uxac084","article-title":"The potential for treg-enhancing therapies in nervous system pathologies","volume":"211","author":"Olson","year":"2022","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.mtbio.2026.103569_bib175","series-title":"Revolutionizing Cancer Therapy: a Comprehensive Review of Immune Checkpoint Inhibitors","author":"Dey","year":"2024"},{"issue":"11","key":"10.1016\/j.mtbio.2026.103569_bib176","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/mds.28218","article-title":"A phase 1 randomized trial of specific active \u03b1\u2010Synuclein immunotherapies PD01A and PD03A in multiple system atrophy","volume":"35","author":"Meissner","year":"2020","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.mtbio.2026.103569_bib177","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1161\/STROKEAHA.122.036946","article-title":"Neuroinflammation, stroke, blood-brain barrier dysfunction, and imaging modalities","volume":"53","author":"Candelario-Jalil","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.mtbio.2026.103569_bib179","series-title":"Pharmacologic NLRP3 Inhibition Modulates Parkinson's Disease-Associated Microglial Transcriptomic Signatures and Mitigates \u03b1-Synuclein\u2013Triggered Neurodegeneration","author":"Luque","year":"2025"},{"key":"10.1016\/j.mtbio.2026.103569_bib180","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2023.1276376","article-title":"Treatment of Parkinson's disease with biologics that penetrate the blood-brain barrier via receptor-mediated transport","volume":"15","author":"Pardridge","year":"2023","journal-title":"Front. Aging Neurosci."},{"issue":"s1","key":"10.1016\/j.mtbio.2026.103569_bib181","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3233\/JPD-223278","article-title":"Therapeutic strategies for immune transformation in Parkinson's disease","volume":"12","author":"Saleh","year":"2022","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.mtbio.2026.103569_bib194","article-title":"Novel therapeutic strategies in targeting alpha synuclein dysfunction pathways for Parkinson's disease treatment","volume":"19","author":"Guduru","year":"2025","journal-title":"Drug Metabol. Bioanal."},{"key":"10.1016\/j.mtbio.2026.103569_bib196","article-title":"Zhu, Tt., Liu, P., Hashimoto, K. et al. Clinical innovations and future directions of nanoparticles in the treatment of psychiatric and neurological disorders. Mol Psychiatry 31, 5114\u20135130 (2026)","author":"Zhu","year":"2026","journal-title":"Mol. Psychiatr."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib197","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/jnt7020012","article-title":"Intrinsically selective nanoplatforms for precision therapy and monitoring","volume":"7","author":"F","year":"2026","journal-title":"J. Nanotheranostics"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib195","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40820-022-00847-z","article-title":"Anti-Parkinsonian therapy: strategies for crossing the blood\u2013brain barrier and nano-biological effects of nanomaterials","volume":"14","author":"Cheng","year":"2022","journal-title":"Nano-Micro Lett."},{"key":"10.1016\/j.mtbio.2026.103569_bib198","series-title":"Challenges in Brain Drug Delivery for Neurodegenerative Disorders and Recent Trends: a Review","author":"Anjukandan","year":"2026"},{"key":"10.1016\/j.mtbio.2026.103569_bib199","series-title":"Nanoparticles and Nanocarriers-based Pharmaceutical Formulations","author":"Jain","year":"2022"},{"issue":"15","key":"10.1016\/j.mtbio.2026.103569_bib200","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2174\/0113894501312703240826070530","article-title":"Trends on novel targets and nanotechnology-based drug delivery system in the treatment of Parkinson's disease: recent advancement in drug development","volume":"25","author":"Majumdar","year":"2024","journal-title":"Curr. Drug Targets"},{"issue":"4","key":"10.1016\/j.mtbio.2026.103569_bib201","article-title":"Recent advances in cell membrane-based biomimetic delivery systems for Parkinson's disease: perspectives and challenges","volume":"20","author":"Kaur","year":"2025","journal-title":"Asian J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib202","first-page":"1","article-title":"Overcoming the blood-brain barrier, strategies and advances in therapeutic delivery: a literature review","volume":"9","author":"Anirud","year":"2025","journal-title":"Undergrad. Res. Nat. Clin. Sci. Technol. J."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib203","doi-asserted-by":"crossref","first-page":"34","DOI":"10.57238\/tpb.2023.144275.1003","article-title":"Nanocarriers and beyond: innovations in overcoming barriers for effective CNS drug delivery","volume":"1","author":"Al-Hamadiny","year":"2023","journal-title":"Trends Pharmaceut. Biotechnol."},{"issue":"10","key":"10.1016\/j.mtbio.2026.103569_bib204","first-page":"1532","article-title":"Research advances in brain-targeted nanoscale drug delivery system","volume":"48","author":"Liu","year":"2013","journal-title":"Acta Pharm. Sin."},{"issue":"9","key":"10.1016\/j.mtbio.2026.103569_bib205","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41551-021-00698-w","article-title":"The evolution of commercial drug delivery technologies","volume":"5","author":"Vargason","year":"2021","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib213","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/pharmaceutics17010109","article-title":"Targeting brain drug delivery with macromolecules through receptor-mediated transcytosis","volume":"17","author":"Li","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mtbio.2026.103569_bib206","first-page":"1","article-title":"Emerging strategies for targeted drug delivery across the blood\u2013brain barrier in neurological disorder","author":"Ali","year":"2025","journal-title":"Curr. Pharmaceut. Res."},{"issue":"10","key":"10.1016\/j.mtbio.2026.103569_bib207","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/jat.2757","article-title":"The point of transition on the dose\u2010effect curve as a reference point in the evaluation ofin vitrotoxicity data","volume":"32","author":"Sand","year":"2012","journal-title":"J. Appl. Toxicol."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib208","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.clpt.2003.11.032","article-title":"Assessment of dose response information in drug labeling","volume":"75","author":"Spyker","year":"2004","journal-title":"Clin. Pharmacol. Therapeut."},{"key":"10.1016\/j.mtbio.2026.103569_bib209","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.69980\/redvet.v25i1.780","article-title":"Innovations in nanocarrier technology for targeted therapeutics: a comprehensive review","author":"Khawas","year":"2024","journal-title":"Revista Electronica de Veterinaria"},{"issue":"4","key":"10.1016\/j.mtbio.2026.103569_bib210","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.21769\/BioProtoc.4334","article-title":"An in vitro blood-brain barrier model to study the penetration of nanoparticles","volume":"12","author":"Aday","year":"2022","journal-title":"Bio-protocol"},{"key":"10.1016\/j.mtbio.2026.103569_bib211","series-title":"Strategies for Transcytosis-based Delivery Across the Blood-Brain Barrier","author":"Baghirov","year":"2025"},{"issue":"9\u201310","key":"10.1016\/j.mtbio.2026.103569_bib212","first-page":"431","article-title":"Latest developments in biomaterial interfaces and drug delivery: challenges, innovations, and future outlook. Zeitschrift Fur Naturforschung. C","volume":"80","author":"Patel","year":"2024","journal-title":"J. Biosci."},{"key":"10.1016\/j.mtbio.2026.103569_bib214","series-title":"Lipid Nanocarriers for Advanced Therapeutic Applications","first-page":"85","author":"Patravale","year":"2018"},{"issue":"6","key":"10.1016\/j.mtbio.2026.103569_bib215","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1038\/s41380-020-0742-4","article-title":"Liposome-based targeting of dopamine to the brain: a novel approach for the treatment of Parkinson's disease","volume":"26","author":"Kahana","year":"2020","journal-title":"Mol. Psychiatr."},{"issue":"4","key":"10.1016\/j.mtbio.2026.103569_bib216","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2174\/2468187310999200818110030","article-title":"A critical review on potential advancements of nanostructured lipid carriers in drug delivery","volume":"10","author":"Kamble","year":"2020","journal-title":"Curr. Nanomed."},{"issue":"24","key":"10.1016\/j.mtbio.2026.103569_bib230","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1021\/acschemneuro.1c00540","article-title":"Engineered solid lipid nanoparticles and nanostructured lipid carriers as new generations of blood-brain barrier transmitters","volume":"12","author":"Amiri","year":"2021","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib231","doi-asserted-by":"crossref","DOI":"10.1515\/tnsci-2022-0359","article-title":"Lipid-based nanoparticles for drug delivery in Parkinson's disease","volume":"15","author":"Cai","year":"2024","journal-title":"Transl. Neurosci."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib232","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1186\/s12951-024-02972-w","article-title":"Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: a quality-by-design approach","volume":"22","author":"Haghighi","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib233","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2174\/0124522716282353240118114732","article-title":"Revolutionizing drug delivery: the potential of PLGA nanoparticles in nanomedicine","volume":"6","author":"Singh","year":"2023","journal-title":"Curr. Appl. Polym. Sci."},{"key":"10.1016\/j.mtbio.2026.103569_bib234","doi-asserted-by":"crossref","DOI":"10.2174\/0113895575417283251127105439","article-title":"The nasal route redefined: the impact of chitosan nanoparticles on drug delivery","volume":"26","author":"Kumar","year":"2026","journal-title":"Mini Rev. Med. Chem."},{"issue":"8","key":"10.1016\/j.mtbio.2026.103569_bib235","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/17435889.2025.2485023","article-title":"Emerging dendrimer-based RNA delivery strategies","volume":"20","author":"Das","year":"2025","journal-title":"Nanomedicine"},{"key":"10.1016\/j.mtbio.2026.103569_bib236","article-title":"A critical review of in vitro and in vivo biomedical applications of gold nanoparticles: from toxicology to cancer therapy","volume":"190","author":"Ozcicek","year":"2025","journal-title":"Biomed.Pharmacother. = Biomed. Pharmacother."},{"key":"10.1016\/j.mtbio.2026.103569_bib237","series-title":"Development of Magnetic Nanoparticles for Targeted Drug Delivery","author":"Dragar","year":"2021"},{"issue":"13","key":"10.1016\/j.mtbio.2026.103569_bib238","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3389\/fphar.2019.01599","article-title":"Variable in vivo and in vitro biological effects of cerium oxide nanoparticle formulations","volume":"10","author":"Heckman","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.mtbio.2026.103569_bib239","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1515\/revneuro-2024-0086","article-title":"Recent advances on brain drug delivery via nanoparticles: alternative future materials for neuroscience applications; a review","volume":"36","author":"Razavi","year":"2025","journal-title":"Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib240","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12035-025-05563-4","article-title":"Advances in intranasal delivery of exosomes for central nervous system disorders","volume":"63","author":"Arjmand","year":"2025","journal-title":"Mol. Neurobiol."},{"issue":"8","key":"10.1016\/j.mtbio.2026.103569_bib241","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3390\/pharmaceutics13081291","article-title":"Polymeric lipid hybrid nanoparticles (PLNs) as emerging drug delivery platform\u2014A comprehensive review of their properties. Preparation methods, and therapeutic applications","volume":"13","author":"Sivadasan","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mtbio.2026.103569_bib242","article-title":"Stimuli-responsive nanoplatforms for central nervous system disorders: integrating delivery, modulation, and imaging","author":"Chen","year":"2026","journal-title":"Chem. Soc. Rev."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib217","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of lipid nanoparticles for RNA delivery","volume":"55","author":"Eygeris","year":"2021","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.mtbio.2026.103569_bib218","series-title":"Polymeric Nanocarriers for Drug Delivery to the Central Nervous System","first-page":"122","author":"Kadam","year":"2024"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib219","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/pharmaceutics17010087","article-title":"Scalable manufacturing method for model protein-loaded PLGA nanoparticles: biocompatibility. Trafficking and release properties","volume":"17","author":"Akpinar Adscheid","year":"2025","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.mtbio.2026.103569_bib220","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1208\/s12249-025-03100-z","article-title":"Chitosan nanoparticles: approaches to preparation, key properties, drug delivery systems, and developments in therapeutic efficacy","volume":"26","author":"Obeidat","year":"2025","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.mtbio.2026.103569_bib221","series-title":"Inorganic Nanoparticles and their Strategies to Enhance Brain Drug Delivery","author":"Gallardo-Toledo","year":"2020"},{"key":"10.1016\/j.mtbio.2026.103569_bib222","series-title":"Iron Oxide-based Nanoparticles in the Living Systems","first-page":"447","article-title":"Persistence, toxicity, and biodegradation of gold","author":"Akhtar","year":"2020"},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib223","first-page":"20","article-title":"Neurotoxic effects of metal and metal oxide nanoparticles and the protective role of natural bioactive compounds","volume":"6","author":"Sahin","year":"2026","journal-title":"Immunology"},{"key":"10.1016\/j.mtbio.2026.103569_bib224","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1274210","article-title":"Editorial: delivery systems in biologics-based therapeutics","volume":"11","author":"Dirisala","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"12","key":"10.1016\/j.mtbio.2026.103569_bib225","doi-asserted-by":"crossref","DOI":"10.31083\/JIN47443","article-title":"The role of exosomes as endogenous nanocarriers for targeted drug delivery: isolation, engineering, and clinical progress in neurological and other diseases","volume":"24","author":"Liu","year":"2025","journal-title":"J. Integr. Neurosci."},{"issue":"25","key":"10.1016\/j.mtbio.2026.103569_bib226","article-title":"Nanoparticles: a hope for the treatment of inflammation in CNS","volume":"12","author":"Zhu","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.mtbio.2026.103569_bib227","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/mco2.643","article-title":"Biomedical applications of stimuli-responsive nanomaterials","volume":"5","author":"Chen","year":"2024","journal-title":"MedComm"},{"issue":"11","key":"10.1016\/j.mtbio.2026.103569_bib228","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202500495","article-title":"Inflamed tissue-targeting polyphenol-condensed antioxidant nanoparticles with therapeutic potential","volume":"14","author":"Jang","year":"2025","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.mtbio.2026.103569_bib229","author":"Abraham","year":"2025"},{"key":"10.1016\/j.mtbio.2026.103569_bib250","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12974-025-03456-w","article-title":"Nanozymes in neuropathic pain: strategies bridging oxidative stress, mitochondrial repair, and neuroimmune modulation for targeted therapy","volume":"22","author":"Mohsin","year":"2025","journal-title":"J. Neuroinflammation"},{"issue":"4","key":"10.1016\/j.mtbio.2026.103569_bib243","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2174\/0126660822306813240516113807","article-title":"CNS delivery systems based on nanotechnology with particular attention to Parkinson's and Alzheimer's disease \u2013A review","volume":"20","author":"Ahmad","year":"2024","journal-title":"Curr. Psychiatr. Res. Rev."},{"issue":"6","key":"10.1016\/j.mtbio.2026.103569_bib244","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1021\/acs.molpharmaceut.9b00489","article-title":"Targeted delivery of anti-inflammatory and imaging agents to microglial cells with polymeric nanoparticles","volume":"17","author":"Cahalane","year":"2020","journal-title":"Mol. Pharm."},{"issue":"11","key":"10.1016\/j.mtbio.2026.103569_bib245","doi-asserted-by":"crossref","first-page":"247","DOI":"10.70749\/ijbr.v3i11.2695","article-title":"Curcumin-loaded nanoparticles for enhanced anti-inflammatory drug delivery in neurodegenerative disorders","volume":"3","author":"Shakeel","year":"2025","journal-title":"Indus J. Biosci. Res."},{"issue":"49","key":"10.1016\/j.mtbio.2026.103569_bib246","article-title":"Neuroinflammation treatment via targeted delivery of nanoparticles","volume":"14","author":"Cerqueira","year":"2020","journal-title":"Front. Cell. Neurosci."},{"issue":"4","key":"10.1016\/j.mtbio.2026.103569_bib247","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11481-009-9176-0","article-title":"Neuroinflammation in Parkinson's disease","volume":"4","author":"Lee","year":"2009","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.mtbio.2026.103569_bib248","article-title":"Advancements in drug delivery for chronic inflammatory diseases: recent approaches and strategies","author":"Saloki","year":"2023","journal-title":"J. Popul. Therapeut. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib249","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2025.2580730","article-title":"Nanotechnology-based targeted regulation of NLRP3 inflammasome: therapeutic strategies and clinical application prospects in inflammatory diseases","volume":"32","author":"Zhao","year":"2025","journal-title":"Drug Deliv."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib251","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3390\/neurolint16030037","article-title":"Oxidative stress and neurodegeneration: insights and therapeutic strategies for Parkinson's disease","volume":"16","author":"Bej","year":"2024","journal-title":"Neurol. Int."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib252","doi-asserted-by":"crossref","DOI":"10.2174\/0122106812340671250108064331","article-title":"A comprehensive review on the role of biofunctionalized nanocarriers in transporting curcumin through the blood-brain barrier","volume":"15","author":"Sahu","year":"2025","journal-title":"Nanosci. Nanotechnol. - Asia"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib253","doi-asserted-by":"crossref","DOI":"10.1002\/pat.70408","article-title":"Injectable thermosensitive hydrogel loaded with selenium nanoparticles: a promising platform for targeted antioxidation therapy","volume":"37","author":"Li","year":"2026","journal-title":"Polym. Adv. Technol."},{"key":"10.1016\/j.mtbio.2026.103569_bib254","doi-asserted-by":"crossref","DOI":"10.1002\/EXP.20210115","article-title":"Mitochondria-targeted nanoparticles in treatment of neurodegenerative diseases","volume":"1","author":"Zhang","year":"2021","journal-title":"Exploration"},{"issue":"22","key":"10.1016\/j.mtbio.2026.103569_bib255","first-page":"2151","article-title":"Nanocarrier-mediated curcumin delivery: an adjuvant strategy for CNS disease treatment","volume":"248","author":"Godse","year":"2023","journal-title":"Exp. Biol. Med."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib262","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/08982104.2023.2290050","article-title":"Development of a brain-targeted nano drug delivery system to enhance the treatment of neurodegenerative effects of resveratrol","volume":"34","author":"Yu","year":"2023","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.mtbio.2026.103569_bib263","series-title":"Sustained GDNF Delivery via PLGA Nanoparticles","author":"Torres Ortega","year":"2020"},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib264","doi-asserted-by":"crossref","first-page":"195","DOI":"10.34107\/LWWJ5713195","article-title":"Thermodynamic study of cerium oxide nanoparticles and their effects on cellular metabolism","volume":"58","author":"Joseph","year":"2022","journal-title":"Biomed. Sci. Instrum."},{"issue":"4","key":"10.1016\/j.mtbio.2026.103569_bib265","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.5530\/ijpi.14.4.112","article-title":"Exploring the therapeutic potential of selenium nanoparticles in central nervous system disorders: a nanomedicine approach","volume":"14","author":"Balaraju","year":"2024","journal-title":"Int. J. Pharm. Investig."},{"issue":"9","key":"10.1016\/j.mtbio.2026.103569_bib266","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70386","article-title":"Exosome\u2010based therapeutics: a natural solution to overcoming the blood\u2013brain barrier in neurodegenerative diseases","volume":"6","author":"Sun","year":"2025","journal-title":"MedComm"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib267","doi-asserted-by":"crossref","DOI":"10.1515\/tnsci-2022-0328","article-title":"Nanopharmacology as a new approach to treat neuroinflammatory disorders","volume":"14","author":"Men\u00e9ndez","year":"2023","journal-title":"Transl. Neurosci."},{"issue":"Suppl 2","key":"10.1016\/j.mtbio.2026.103569_bib268","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3389\/fchem.2020.00838","article-title":"Biomedical application of reactive oxygen species-responsive nanocarriers in cancer, inflammation, and neurodegenerative diseases","volume":"8","author":"Liu","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.mtbio.2026.103569_bib256","article-title":"Brain Targeted Nanocarriers: A Revolutionary Approach for Treating Neurodegenerative Disorders","author":"Sharma","year":"2025","journal-title":"EJPPS Eur. J. Parenter. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib257","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102671","article-title":"Nose-to-brain siRNA delivery by PEI\/PPI-based nanoparticles reduces \u03b1-synuclein expression in a Parkinson's disease mouse model","volume":"36","author":"Feja","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"10","key":"10.1016\/j.mtbio.2026.103569_bib258","first-page":"1","article-title":"Nanotherapeutic interventions for Parkinson's disease: modulating pathogenic mechanisms and overcoming therapeutic obstacles","volume":"21","author":"Yin","year":"2026","journal-title":"Int. J. Nanomed."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib259","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s13346-025-01799-8","article-title":"Nanotechnology in Parkinson's disease: overcoming drug delivery challenges and enhancing therapeutic outcomes","volume":"16","author":"Ali","year":"2025","journal-title":"Drug Deliv. Transl. Res."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib260","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1186\/s12951-024-02681-4","article-title":"Exosomes as therapeutic and drug delivery vehicle for neurodegenerative diseases","volume":"22","author":"Nouri","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib261","doi-asserted-by":"crossref","DOI":"10.37819\/hb.1.1810","article-title":"Potential applications of nanomedicine in the treatment of Parkinson's disease","volume":"3","author":"Xu","year":"2024","journal-title":"Human Brain"},{"issue":"116","key":"10.1016\/j.mtbio.2026.103569_bib269","article-title":"Parkinson's disease: a nanotheranostic approach targeting alpha-synuclein aggregation","volume":"9","author":"Zoey","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.mtbio.2026.103569_bib278","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.707441","article-title":"Parkinson's disease: a nanotheranostic approach targeting alpha-synuclein aggregation","volume":"9","author":"Zoey","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"27","key":"10.1016\/j.mtbio.2026.103569_bib270","doi-asserted-by":"crossref","first-page":"7919","DOI":"10.1039\/D5TB00295H","article-title":"Nanozymes in Parkinson's disease: strategic approaches, clinical considerations, and challenges","volume":"13","author":"Huang","year":"2025","journal-title":"J. Mater. Chem. B"},{"issue":"7","key":"10.1016\/j.mtbio.2026.103569_bib271","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1007\/s12035-023-03846-2","article-title":"Molecular chaperones as therapeutic target: hallmark of neurodegenerative disorders","volume":"61","author":"Sharma","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.mtbio.2026.103569_bib272","series-title":"A brain-shuttled Antibody Targeting Alpha Synuclein Aggregates for the Treatment of Synucleinopathies","author":"An","year":"2024"},{"issue":"7","key":"10.1016\/j.mtbio.2026.103569_bib273","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.1007\/s12035-025-04788-7","article-title":"Biology, pathology, and targeted therapy of exosomal cargoes in Parkinson's disease: advances and challenges","volume":"62","author":"Almasi","year":"2025","journal-title":"Mol. Neurobiol."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib274","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1021\/acs.biochem.4c00667","article-title":"Deciphering the seed size-dependent cellular internalization mechanism for \u03b1-Synuclein fibrils","volume":"64","author":"Sakunthala","year":"2025","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.mtbio.2026.103569_bib275","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s12274-020-2748-2","article-title":"Effect of metallic nanoparticles on amyloid fibrils and their influence to neural cell toxicity","volume":"13","author":"Barbalinardo","year":"2020","journal-title":"Nano Res."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib276","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5607\/en21039","article-title":"Conformation-specific antibodies targeting aggregated forms of \u03b1-synuclein block the propagation of synucleinopathy","volume":"31","author":"Choi","year":"2022","journal-title":"Exp. Neurobiol."},{"issue":"44","key":"10.1016\/j.mtbio.2026.103569_bib277","article-title":"Nanoparticles with affinity for \u03b1-Synuclein sequester \u03b1-Synuclein to form toxic aggregates in neurons with endolysosomal impairment","volume":"14","author":"Jiang","year":"2021","journal-title":"Front. Mol. Neurosci."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib279","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/NRR.NRR-D-23-01195","article-title":"The autophagy-lysosome pathway: a potential target in the chemical and gene therapeutic strategies for Parkinson's disease","volume":"20","author":"Jiao","year":"2024","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.mtbio.2026.103569_bib280","series-title":"Tbc1d15 Knockdownin Vivoalleviates \u03b1-synuclein-induced Neurotoxicity by Promoting Autophagy","author":"Siddiqi","year":"2024"},{"issue":"9","key":"10.1016\/j.mtbio.2026.103569_bib281","first-page":"813","article-title":"Rescuing lysosomal\/autophagic defects via nanoapproach: implications for lysosomal\/autophagic defect-related diseases. Journal of Zhejiang University","volume":"26","author":"Huang","year":"2025","journal-title":"Science. B"},{"issue":"6","key":"10.1016\/j.mtbio.2026.103569_bib282","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1002\/med.21718","article-title":"Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era","volume":"40","author":"Li","year":"2020","journal-title":"Med. Res. Rev."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib287","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3390\/ijms23020760","article-title":"Nanocarriers for delivery of oligonucleotides to the CNS","volume":"23","author":"Gromnicova","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.mtbio.2026.103569_bib283","doi-asserted-by":"crossref","first-page":"8904","DOI":"10.1007\/s12274-024-6748-5","article-title":"Viral and nonviral nanocarriers for in vivo CRISPR-based gene editing","volume":"17","author":"Guo","year":"2024","journal-title":"Nano Res."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib284","doi-asserted-by":"crossref","DOI":"10.1063\/5.0013178","article-title":"Microglia-targeting nanotherapeutics for neurodegenerative diseases","volume":"4","author":"Zhao","year":"2020","journal-title":"APL Bioeng."},{"key":"10.1016\/j.mtbio.2026.103569_bib285","series-title":"Recent Progress in Nanotheranostic Medicine","author":"Sahoo","year":"2020"},{"issue":"13","key":"10.1016\/j.mtbio.2026.103569_bib286","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202310404","article-title":"Alpha-synuclein oligomers driven T1-T2 switchable nanoprobes for early and accurate diagnosis of Parkinson's disease","volume":"36","author":"Chen","year":"2023","journal-title":"Adv. Mater."},{"issue":"1630475","key":"10.1016\/j.mtbio.2026.103569_bib306","article-title":"Harnessing nanotechnology for stem-cell therapies: revolutionizing neurodegenerative disorder treatments \u2013 a state-of-the-art update","volume":"16","author":"Chengebroyen","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib288","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41531-019-0105-5","article-title":"Emerging regenerative medicine and tissue engineering strategies for Parkinson\\u2019s disease","volume":"6","author":"Harris","year":"2020","journal-title":"npj Parkinson's Dis."},{"issue":"4","key":"10.1016\/j.mtbio.2026.103569_bib289","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40005-021-00521-3","article-title":"Development of immunotherapy and nanoparticles-based strategies for the treatment of Parkinson's disease","volume":"51","author":"Duwa","year":"2021","journal-title":"J. Pharm. Investig."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib290","article-title":"Advances in clinical neurorestorative treatments of Parkinson's disease","volume":"13","author":"Yin","year":"2025","journal-title":"J. Neurorestoratol."},{"key":"10.1016\/j.mtbio.2026.103569_bib291","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.reth.2025.04.011","article-title":"Research status of regenerative difficulties after central nervous system injury","volume":"29","author":"Fu","year":"2025","journal-title":"Regen. Ther."},{"key":"10.1016\/j.mtbio.2026.103569_bib292","series-title":"Neural Stem Cells, and the Path to Neural Tissue Engineering","first-page":"99","article-title":"Nanomaterials","author":"Dubey","year":"2022"},{"issue":"8","key":"10.1016\/j.mtbio.2026.103569_bib293","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/mds.28628","article-title":"Recent advances in the development of stem-cell-derived dopaminergic neuronal transplant therapies for Parkinson's disease","volume":"36","author":"Barbuti","year":"2021","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.mtbio.2026.103569_bib294","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2217\/nnm-2019-0103","article-title":"Recent advances in the use of magnetic nanoparticles to promote neuroregeneration","volume":"14","author":"Falconieri","year":"2019","journal-title":"Nanomedicine"},{"issue":"3","key":"10.1016\/j.mtbio.2026.103569_bib295","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2174\/1574888X16666210719110436","article-title":"A review of recent advances in nanomaterial-based stem cell therapy and the corresponding risks","volume":"17","author":"Tian","year":"2022","journal-title":"Curr. Stem Cell Res. Ther."},{"issue":"e1801362","key":"10.1016\/j.mtbio.2026.103569_bib296","article-title":"Neurotrophic factors in Parkinson's disease: clinical trials, open challenges and nanoparticle-mediated delivery to the brain","volume":"15","author":"Bondarenko","year":"2021","journal-title":"Front. Cell. Neurosci."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib297","doi-asserted-by":"crossref","first-page":"1","DOI":"10.29245\/2572.942X\/2025\/1.1311","article-title":"Nanomedicine: transforming neurological therapies and precision medicine","volume":"9","author":"Ikram","year":"2025","journal-title":"J. Neurol. Neuromed."},{"issue":"13","key":"10.1016\/j.mtbio.2026.103569_bib298","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.3390\/nano12132267","article-title":"Self-assembled nanoscale materials for neuronal regeneration: a focus on BDNF protein and nucleic acid biotherapeutic delivery","volume":"12","author":"Wu","year":"2022","journal-title":"Nanomaterials"},{"issue":"27009","key":"10.1016\/j.mtbio.2026.103569_bib299","article-title":"A state-of-the-art of functional scaffolds for 3D nervous tissue regeneration","volume":"9","author":"Tupone","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"46","key":"10.1016\/j.mtbio.2026.103569_bib300","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202104887","article-title":"Graphene\u2010based nanomaterials for neuroengineering: recent advances and future prospective","volume":"31","author":"Kumar","year":"2021","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.mtbio.2026.103569_bib301","article-title":"Extracellular Nanomatrix-Induced Self-Organization of Neural Stem Cells into Miniature Substantia Nigra-Like Structures with Therapeutic Effects on Parkinsonian Rats","volume":"6","author":"Zhang","year":"2019","journal-title":"Adv. Sci."},{"issue":"7","key":"10.1016\/j.mtbio.2026.103569_bib302","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1021\/acsabm.5c00096","article-title":"Unveiling exosome potential: transforming treatments for neurodegeneration","volume":"8","author":"Tiwari","year":"2025","journal-title":"ACS Appl. Bio Mater."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib303","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12272-023-01428-3","article-title":"Distinctive role of inflammation in tissue repair and regeneration","volume":"46","author":"Choi","year":"2023","journal-title":"Arch. Pharm. Res."},{"issue":"11","key":"10.1016\/j.mtbio.2026.103569_bib304","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3109\/00207454.2011.598981","article-title":"Astrocytes and microglia: responses to neuropathological conditions","volume":"121","author":"Singh","year":"2011","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.mtbio.2026.103569_bib305","series-title":"ChemRxiv","article-title":"Novel therapeutic applications of stem cell-derived exosomes in enhancing neurological regeneration and repair","author":"Farmahini Farahani","year":"2024"},{"key":"10.1016\/j.mtbio.2026.103569_bib317","doi-asserted-by":"crossref","DOI":"10.2147\/IJN.S570452","article-title":"Nanotherapeutic interventions for Parkinson's disease: modulating pathogenic mechanisms and overcoming therapeutic obstacles","volume":"21","author":"Yin","year":"2026","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib307","article-title":"The effects of nanotechnology and Theranostic on neurodegenerative diseases","volume":"6","author":"Otero","year":"2024","journal-title":"Chem. Pharmaceut. Res."},{"key":"10.1016\/j.mtbio.2026.103569_bib308","series-title":"Toxicity of Nanomaterials-Physicochemical Effects","first-page":"140","author":"Morteza Naghib","year":"2023"},{"issue":"10391","key":"10.1016\/j.mtbio.2026.103569_bib309","doi-asserted-by":"crossref","first-page":"15493","DOI":"10.2147\/IJN.S558540","article-title":"Targeted-immunomodulatory nanomedicines for the treatment of autoimmune diseases via multiple administration routes","volume":"20","author":"Lee","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.mtbio.2026.103569_bib310","series-title":"Brain-Targeted Drug Delivery with Surface-Modified Nanoparticles","author":"Lahkar","year":"2019"},{"issue":"12","key":"10.1016\/j.mtbio.2026.103569_bib311","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/03639045.2025.2555858","article-title":"Cutting-edge strategies for delivering drugs to the brain based on nanocarriers","volume":"51","author":"Shaw","year":"2025","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"Suppl 7_1","key":"10.1016\/j.mtbio.2026.103569_bib312","article-title":"Cell based nano therapeutic for drug delivery in a Parkinson's mouse model (P5-3.010","volume":"104","author":"Stone","year":"2025","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.mtbio.2026.103569_bib313","first-page":"149","article-title":"Towards sustainable Scaling-Up of nanomaterials fabrication: current situation, challenges, and future perspectives","volume":"6","author":"Hachhach","year":"2025","journal-title":"Engineer"},{"key":"10.1016\/j.mtbio.2026.103569_bib314","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.52711\/0974-360X.2025.00659","article-title":"Recent advances in controlled drug delivery systems: patent, future prospects and challenges","author":"Tonk","year":"2025","journal-title":"Res. J. Pharm. Technol."},{"key":"10.1016\/j.mtbio.2026.103569_bib315","series-title":"Introduction to Nanomedicine and Nanopharmaceuticals","author":"Beus","year":"2024"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib316","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s11671-024-04118-1","article-title":"Comprehensive insights into mechanism of nanotoxicity, assessment methods and regulatory challenges of nanomedicines","volume":"19","author":"Havelikar","year":"2024","journal-title":"Discover Nano"},{"issue":"4","key":"10.1016\/j.mtbio.2026.103569_bib318","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s00415-025-13049-5","article-title":"Biological frameworks for Parkinson's disease: the heterogeneity SAAgged","volume":"272","author":"Landolfi","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.mtbio.2026.103569_bib319","series-title":"The Future of Preventive Neurology?","first-page":"7","article-title":"A blood biomarker-guided precision medicine approach for individualized neurodegenerative disease risk reduction and treatment","author":"Niotis","year":"2025"},{"key":"10.1016\/j.mtbio.2026.103569_bib320","article-title":"From microfluidics to nanodelivery: artificial intelligence reshapes neuropharmacology research strategies","volume":"17","author":"Chen","year":"2026","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.mtbio.2026.103569_bib321","series-title":"Emerging Use of bio-nanomaterials for Brain Pathologies","author":"Noor","year":"2026"},{"key":"10.1016\/j.mtbio.2026.103569_bib325","first-page":"5","article-title":"Interest continues in GM-1 as therapy for neuronal injury","volume":"908","author":"Mundell","year":"1993","journal-title":"Inpharma Weekly"},{"issue":"Suppl 15","key":"10.1016\/j.mtbio.2026.103569_bib326","article-title":"Risks and benefits of phase I trials: eighteen-year experience from a single institution","volume":"35","author":"Kam","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib327","article-title":"Cerium oxide nanoparticles: a promising nanotherapy approach for chronic degenerative diseases","volume":"20","author":"Monroy-Ramirez","year":"2025","journal-title":"J. Mater. Sci.: Mater. Eng."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103569_bib328","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3390\/pharmaceutics15020621","article-title":"Cell-membrane-coated nanoparticles for targeted drug delivery to the brain for the treatment of neurological diseases","volume":"15","author":"Li","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103569_bib329","doi-asserted-by":"crossref","first-page":"81","DOI":"10.17975\/sfj-2024-007","article-title":"CRISPR technology for Parkinson's disease: recent advancements and ongoing challenges","volume":"10","author":"Mathur","year":"2024","journal-title":"STEM Fellowship J."},{"issue":"7","key":"10.1016\/j.mtbio.2026.103569_bib322","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3233\/JPD-240353","article-title":"Clinical trial highlights: anti-inflammatory and immunomodulatory agents","volume":"14","author":"Patel","year":"2024","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.mtbio.2026.103569_bib323","series-title":"Advancements in Nanomedicine for Neurodegenerative Diseases: a Comprehensive Review","author":"Chauhan","year":"2024"},{"key":"10.1016\/j.mtbio.2026.103569_bib324","series-title":"Harnessing AI for Revolutionary Healthcare Transformation in Nanotechnology","first-page":"364","author":"Darwish","year":"2025"},{"issue":"7","key":"10.1016\/j.mtbio.2026.103569_bib330","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3390\/cells12071012","article-title":"Microglia mediated neuroinflammation in Parkinson's disease","volume":"12","author":"Isik","year":"2023","journal-title":"Cells"}],"container-title":["Materials Today Bio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590006426008148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590006426008148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:41:22Z","timestamp":1790336482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590006426008148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":330,"alternative-id":["S2590006426008148"],"URL":"https:\/\/doi.org\/10.1016\/j.mtbio.2026.103569","relation":{},"ISSN":["2590-0064"],"issn-type":[{"value":"2590-0064","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From neuroinflammation to immune reprogramming: Nanozyme-Integrated nanoplatforms for neuroimmune modulation in Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Materials Today Bio","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mtbio.2026.103569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103569"}}